Ph+ chronic granuloma taking imatinib depends on the actual situation of the patient, may be 400-800mg/day, please follow the doctor’s instructions. Imatinib can be used to treat Philadelphia chromosome-positive chronic granulocytic leukemia (Ph +CML) in the chronic, accelerated, or acute phase. The recommended dose of imatinib mesylate is 400 mg/day for patients in the chronic phase and 600 mg/day for patients in the acute and accelerated phases. In addition, disease progression has occurred at any time, a satisfactory hematologic response has not been achieved after at least 3 months of treatment, no cytogenetic response has been achieved after 12 months of treatment, and the hematologic and/or cytogenetic response achieved has receded. In the absence of serious adverse drug reactions and if blood picture permits, the dose may be considered to be increased from 400 mg/day to 600 mg/day or from 600 mg/day to 800 mg/day. Patients are advised to follow the doctor’s instructions and treat actively, and not to be impatient or discontinue the drug blindly to avoid delaying or aggravating the condition.